

Supplementary material

for

**Multistep Synthesis and *In Vitro* Anticancer Evaluation of 2-Pyrazolyl-Estradiol Derivatives,
Pyrazolocoumarin-Estradiol Hybrids and Analogous Compounds**

Barnabás Molnár ¹, Mohana Krishna Gopisetty ², Dóra Izabella Adamecz ², Mónika Kiricsi ²
and Éva Frank ^{1,*}



¹ *Department of Organic Chemistry, Doctoral School of Chemistry, University of Szeged, Dóm tér 8, H-6720 Szeged, Hungary*

² *Department of Biochemistry and Molecular Biology, Doctoral School of Biology, University of Szeged, Közép fasor 52, H-6726, Szeged, Hungary*


*Corresponding author. E-mail address: frank@chem.u-szeged.hu

Table of Contents


¹ H NMR and ¹³ C NMR spectra of the synthesized compounds	S2-S28
Mean±SD values of primary growth inhibitory screen (given as cell viability) used to construct the heat map (Table S1)	S29
Dose response curves used to evaluate IC50 concentrations of selected compounds. (Figure S1)	S30

1H — 2018-11-06T08:35:32 — CDCl₃13C — 2018-11-06T08:48:59 — CDCl₃


1H — 2020-01-18T04:44:07 — CDCl3




13C — 2020-01-18T04:57:32 — CDCl3




1H — 2018-11-22T13:50:50 — CDCl3




13C — 2018-11-22T14:04:16 — CDCl3




1H — 2019-03-29T09:18:36 — CDCl3




13C — 2019-03-29T09:32:00 — CDCl3




1H — 2019-03-15T04:13:12 — CDCl3




13C — 2019-03-15T04:26:36 — CDCl3





1H — 2020-01-18T05:02:16 — CDCl3




13C — 2020-01-18T05:15:42 — CDCl3




1H — 2020-01-18T05:20:28 — CDCl₃13C — 2020-01-18T05:33:53 — CDCl₃


1H — 2020-01-18T05:38:54 — CDCl3




13C — 2020-01-18T05:52:19 — CDCl3





1H — 2018-12-05T15:28:00 — CDCl3




13C — 2018-12-05T15:41:26 — CDCl3






1H — 2019-03-29T10:20:39 — CDCl₃13C — 2019-03-29T10:34:03 — CDCl₃



1H — 2019-03-29T09:36:54 — CDCl3




13C — 2019-03-29T09:53:00 — CDCl3




1H — 2018-12-05T15:10:50 — CDCl₃13C — 2018-12-05T15:24:18 — CDCl₃

1H — 2019-03-29T10:38:04 — CDCl₃13C — 2019-03-29T10:51:28 — CDCl₃


1H — 2020-01-18T05:57:11 — DMSO




13C — 2020-01-18T06:10:54 — DMSO




1H — 2019-03-29T10:38:04 — CDCl3




13C — 2019-03-29T10:51:28 — CDCl3




1H — 2020-01-18T06:15:23 — DMSO




13C — 2020-01-18T06:28:49 — DMSO




1H — 2019-02-27T17:01:00 — CDCl3




13C — 2019-02-27T17:14:24 — CDCl3




1H — 2019-02-28T22:45:14 — CDCl3




13C — 2019-02-28T22:58:38 — CDCl3




1H — 2019-06-27T13:55:37 — CDCl3




13C — 2019-06-27T14:13:25 — CDCl3




1H — 2019-06-27T19:03:10 — CDCl3




13C — 2019-06-27T19:16:33 — CDCl3




1H — 2019-04-18T21:21:00 — CDCl3




13C — 2019-04-18T21:34:25 — CDCl3







1H — 2019-06-27T18:44:46 — CDCl3




13C — 2019-06-27T18:58:11 — CDCl3




1H — 2019-06-27T19:38:38 — CDCl₃13C — 2019-06-27T19:52:03 — CDCl₃

1H — 2019-04-18T21:03:39 — CDCl₃13C — 2019-04-18T21:17:03 — CDCl₃


1H — 2019-06-27T18:24:57 — CDCl3



13C — 2019-06-27T18:40:08 — CDCl3



1H — 2019-06-27T19:20:54 — CDCl3



13C — 2019-06-27T19:34:18 — CDCl3




Table S1: Mean \pm SD values of primary growth inhibitory screen (given as cell viability) used to construct the heat map

	MRC-5	MCF-7	HeLa	PC-3	DU145
Control	99.9 \pm 7.2	100 \pm 3.6	100.0 \pm 3.1	99.9 \pm 7.6	100.0 \pm 13.9
4	\geq 100 \pm 6.6	92.7 \pm 2.2	90.0 \pm 4.3	88.5 \pm 6.5	94.2 \pm 8.6
5	\geq 100 \pm 7	87.5 \pm	99.6 \pm 3.5	79.0 \pm 3.8	100.6 \pm 6.5
7a	\geq 100 \pm 5.7	98.6 \pm 5.2	102.7 \pm 2.7	87.8 \pm 7.1	108.7 \pm 9.1
7b	100.4 \pm 5.1	\geq 100 \pm 4.3	100.1 \pm 2.1	98.2 \pm 6.5	98.7 \pm 15.6
7c	78.9 \pm 4.3	57.4 \pm 10.6	94.1 \pm 1.9	36.0 \pm 4.5	70.4 \pm 3.6
8a	99.9 \pm 3.3	100.9 \pm 4.8	100.4 \pm 1.6	54.9 \pm 3.0	108.8 \pm 4.1
8b	\geq 100 \pm 2.4	\geq 100 \pm 8.2	92.2 \pm 8.5	67.8 \pm 3.8	\geq 100 \pm 10.2
8c	\geq 100 \pm 3.3	\geq 100 \pm 5.3	83.1 \pm 6.2	94.8 \pm 4.0	\geq 100 \pm 5.0
9a	\geq 100 \pm 8.1	\geq 100 \pm 2.4	73.8 \pm 0.6	82.0 \pm 2.2	\geq 100 \pm 5.8
9b	\geq 100 \pm 4.2	\geq 100 \pm 0.8	68.0 \pm 0.4	86.2 \pm 2.4	\geq 100 \pm 4.5
9c	89.5 \pm 8.7	91.1 \pm 3.1	75.7 \pm 1.7	94.1 \pm 4.2	\geq 100 \pm 0.9
10a	93.6 \pm 1.7	73.5 \pm 7.2	83.2 \pm 2.0	63.6 \pm 17.8	\geq 100 \pm 15.8
10b	96.9 \pm 3.8	87.6 \pm 0.7	68.3 \pm 2.2	88.0 \pm 5.6	\geq 100 \pm 6.8
10c	96.4 \pm 10.1	63.2 \pm 2.2	72.4 \pm 4.2	81.6 \pm 6.8	77.3 \pm 6.3
11a	\geq 100 \pm 8.2	93.4 \pm 3.7	75.4 \pm 1.1	59.7 \pm 3.2	98.2 \pm 5.4
11b	\geq 100 \pm 2.2	80.4 \pm 2.9	70.1 \pm 4.5	74.3 \pm 2.3	97.5 \pm 10.1
11c	\geq 100 \pm 8.4	\geq 100 \pm 0.7	77.9 \pm 1.5	87.1 \pm 3.8	127.1 \pm 4.9
15	\geq 100 \pm 3.7	\geq 100 \pm 1.9	53.8 \pm 8.3	\geq 100 \pm 2.2	\geq 100 \pm 6.7
17a	\geq 100 \pm 7.3	\geq 100 \pm 2.3	53.7 \pm 3.3	71.0 \pm 20.9	\geq 100 \pm 6.4
17b	\geq 100 \pm 14.5	93.2 \pm 6.0	\geq 100 \pm 3.9	\geq 100 \pm 3.0	\geq 100 \pm 16.8
17c	\geq 100 \pm 4.0	77.5 \pm 4.6	\geq 100 \pm 4.0	61.9 \pm 2.8	80.3 \pm 10.8
18a	\geq 100 \pm 0.1	98.0 \pm 7.1	\geq 100 \pm 6.5	91.5 \pm 12.9	87.0 \pm 18.2
18b	\geq 100 \pm 2.6	\geq 100 \pm 5.3	\geq 100 \pm 8.7	99.6 \pm 7.7	45.3 \pm 2.5
18c	\geq 100 \pm 2.3	\geq 100 \pm 4.7	\geq 100 \pm 6.6	90.9 \pm 3.0	\geq 100 \pm 4.3
19a	\geq 100 \pm 3.0	\geq 100 \pm 3.9	\geq 100 \pm 8.7	95.4 \pm 1.3	21.6 \pm 0.5
19b	\geq 100 \pm 0	\geq 100 \pm 4.8	\geq 100 \pm 2.4	84.1 \pm 5.2	100.6 \pm 6.3
19c	\geq 100 \pm 2.5	\geq 100 \pm 3.8	\geq 100 \pm 8.3	79.1 \pm 7.8	\geq 100.6 \pm 10.8




Figure S1: Dose response curves used to evaluate IC_{50} concentrations of selected compounds. X-axis represents nM concentrations of the test compound and μM concentration of cisplatin on logarithmic scale and Y-axis represents cell viability normalized to untreated control.